Fidelity Investments

Saluda Medical Pty Ltd. is a medical device company focused on developing innovative solutions for the neuromodulation industry. The firm is known for its investigational device, Evoke, which features a closed-loop spinal cord stimulation system. This technology measures the spinal cord's response to stimulation and adjusts the stimulation parameters in real-time to optimize therapeutic outcomes for patients. Founded in 2010 and headquartered in Artarmon, Australia, with additional offices in Minnesota and the United Kingdom, Saluda Medical aims to provide effective treatment for chronic neuropathic pain. The company's unique approach involves monitoring each patient's neural fingerprint to automatically tailor electrical stimulation, ensuring that therapy is customized to meet individual needs. Saluda Medical's commitment to advancing medical technology is underpinned by a strong foundation of scientific research and a team of experienced professionals.

Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.

Dianthus Therapeutics is a biotech company operating in stealth mode. It was founded in 2019 and is based in Waltham, Massachusetts.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

Saluda Medical Pty Ltd. is a medical device company focused on developing innovative solutions for the neuromodulation industry. The firm is known for its investigational device, Evoke, which features a closed-loop spinal cord stimulation system. This technology measures the spinal cord's response to stimulation and adjusts the stimulation parameters in real-time to optimize therapeutic outcomes for patients. Founded in 2010 and headquartered in Artarmon, Australia, with additional offices in Minnesota and the United Kingdom, Saluda Medical aims to provide effective treatment for chronic neuropathic pain. The company's unique approach involves monitoring each patient's neural fingerprint to automatically tailor electrical stimulation, ensuring that therapy is customized to meet individual needs. Saluda Medical's commitment to advancing medical technology is underpinned by a strong foundation of scientific research and a team of experienced professionals.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on enhancing healthcare delivery through innovative drug development. The company aims to reduce the time and cost associated with bringing new medicines to market, sharing those savings with the healthcare system. Roivant achieves this by creating specialized entities known as Vants, which are agile biotech and healthcare technology firms that leverage unique talent sourcing and technology deployment strategies. In addition to its biopharmaceutical subsidiaries, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its drug candidates, VTAMA (tapinarof) is designed for the treatment of plaque psoriasis and has reached the commercial stage, while several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, are in various stages of development.

Laronde is focused on developing innovative therapeutics using its proprietary Endless RNA™ (eRNA) platform, which allows for the modulation of human biology through uniquely engineered RNA. This technology enables the expression of diverse proteins within the body while being persistent, non-immunogenic, and suitable for repeat dosing. Additionally, it provides flexibility in formulation and delivery, making it a promising foundation for new medicines. Founded in 2017 by Flagship Labs, Laronde is rapidly scaling its operations to support the simultaneous development of various programs targeting multiple disease areas, aiming to create more predictable and impactful treatments in the healthcare sector.

Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Aristea Therapeutics is a clinical-stage drug development company based in San Diego, California, founded in 2018. The company focuses on creating novel therapies for serious inflammatory diseases and autoimmune conditions. Its research and development efforts are concentrated on addressing unmet medical needs for patients suffering from various conditions, including palmoplantar pustulosis, hidradenitis suppurativa, inflammatory bowel disease, familial Mediterranean fever, and Behçet's disease. By employing a focused and agile approach, Aristea aims to provide innovative treatment options that improve patient outcomes in these challenging therapeutic areas.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases. ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Emalex Biosciences is a biopharmaceutical company focused on developing innovative treatments for patients suffering from central nervous system disorders, particularly those with limited or no existing treatment options. The company is advancing its investigational medicine, ecopipam, aimed at addressing fluency disorders and Tourette Syndrome. Emalex also collaborates with patient advocacy organizations and medical researchers to enhance the understanding and treatment of rare neurological conditions. Through its efforts, the company seeks to provide effective solutions for individuals affected by these challenging disorders.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.

Vera Therapeutics is engaged in the development of innovative gene editing solutions aimed at curing genetic diseases, particularly sickle cell disease and cystic fibrosis. The company utilizes a proprietary triplex gene editing platform to create a pipeline of therapeutic products targeting high-penetrance disease genes. Founded in 2016 and based in South San Francisco, California, Vera Therapeutics is dedicated to alleviating and potentially curing genetic disorders in affected patients.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Prelude Therapeutics is a clinical-stage biopharmaceutical company based in Wilmington, Delaware, founded in 2016. The company focuses on discovering and developing small molecule therapies designed to target critical mechanisms driving cancer growth and resistance. Its pipeline includes several candidates currently in Phase 1 clinical trials, such as PRT543, aimed at treating solid tumors and myeloid malignancies, and PRT811, which targets solid tumors like glioblastoma multiforme. Other development programs include PRT1419, a selective inhibitor of an anti-apoptotic protein, PRT2527, an inhibitor of CDK9, PRT-SCA2 for genomically selected cancers, and PRT-K4 for solid tumors. Prelude Therapeutics aims to provide innovative treatment options for patients facing refractory cancers.

Conformal Medical, Inc. is a medical device company focused on developing innovative solutions to prevent strokes in patients with atrial fibrillation (AFib), particularly those with non-valvular AFib. Founded in 2016 and headquartered in Nashua, New Hampshire, the company offers CLAAS Technology, which facilitates the sealing of the left atrial appendage (LAA) through its conformal left atrial appendage closure (LAAC) system. This proprietary technology is designed to adapt to the unique anatomy of each patient, enhancing the effectiveness of LAA closure procedures. By enabling healthcare professionals to treat patients at risk of stroke more effectively, Conformal Medical aims to improve clinical outcomes and save lives.

Taysha Gene Therapies is a company focused on developing adeno-associated virus (AAV) based gene therapies aimed at treating monogenic diseases of the central nervous system. Founded in 2019 and based in Dallas, Texas, the company is advancing several therapeutic candidates, including TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies collaborates with The University of Texas Southwestern Medical Center to enhance the development and commercialization of its innovative treatments, with a mission to eradicate severe and life-threatening CNS diseases through curative gene therapies. The company's expertise in drug development and its partnership with a leading gene therapy program enable it to effectively progress its pipeline of potential therapies.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.

Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.

Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. Founded in 2016, the company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create dual-function fusion proteins that enhance immune responses against tumors. Its lead product candidate, SL-172154, is currently undergoing a Phase 1 clinical trial for ovarian cancer, designed to inhibit the CD47/SIRPa checkpoint interaction while activating the CD40 costimulatory receptor. Additionally, Shattuck collaborates with Takeda Pharmaceuticals on SL-279252, also in Phase 1 trials, which targets the PD-1/PD-L1 interaction and activates the OX40 receptor to improve anti-tumor immunity. Through its innovative approaches, Shattuck Labs aims to advance the field of immuno-oncology and provide effective treatments for various malignancies.

Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.

Dragonfly Therapeutics, Inc. develops drugs to stimulate immune responses against cancer using its platform TriNKET. Dragonfly Therapeutics, Inc. has strategic collaborations with Celgene Corporation and Merck. The company was founded in 2015 and is based in Waltham, Massachusetts.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

Think Research is a Canada-based healthcare technology company that specializes in providing knowledge-based tools and clinical content to clinicians at the point of care. Founded in 2006, the company addresses the complex challenges faced by healthcare organizations, such as health system reform and quality improvement, by offering practical and cost-effective solutions. Its services include knowledge translation, partner applications like eMED-PASS and how2track, and various platforms designed to enhance clinical practice. By utilizing ontologic and semantic-based artificial intelligence and machine learning, Think Research improves the utilization of patient data. The company delivers its Software-as-a-Service solutions globally to a diverse range of clients, including hospitals, health regions, healthcare professionals, and government entities, thereby facilitating better healthcare outcomes across various care settings.

Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.

Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.

Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Kaleido Biosciences is a clinical-stage healthcare company based in Lexington, Massachusetts, dedicated to developing microbiome metabolic therapies (MMTs) aimed at treating various diseases and improving human health. Founded in 2015, the company is advancing a diverse pipeline of MMT candidates targeting conditions such as urea cycle disorders, hepatic encephalopathy, multi-drug resistant infections, cardiometabolic and liver diseases, and immune oncology. Kaleido employs a unique, chemistry-driven approach to harness the microbiome's potential, focusing on modulating its metabolic output and profile by influencing the existing microbial functions. The company has established collaborations with notable institutions, including Gustave Roussy Cancer Center and Washington University School of Medicine, to further explore the applications of MMTs in immuno-oncology and other health conditions.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Medibio Limited is a health technology company focused on the research, development, and commercialization of mental health solutions aimed at the screening, diagnosis, monitoring, and management of depression and related disorders. Operating in Australia and the United States, the company provides mental well-being solutions for businesses and develops products for healthcare providers. Medibio has created an objective test based on circadian heart rate variability, which utilizes proprietary algorithms to deliver quantifiable measures for clinical diagnosis. This test is undergoing validation in clinical studies conducted by reputable institutions, including Johns Hopkins University School of Medicine and The University of Ottawa, to support its application for FDA approval. Additionally, Medibio's technology is applicable in workplace stress and well-being markets, as well as in wearable technology and app development. Originally founded as BioProspect Limited in 1987, Medibio rebranded in 2014 and operates offices in Melbourne and the United States.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California. Founded in 2010, the company specializes in the development of innovative therapies in immunology and inflammation, particularly targeting dermatological conditions. Its lead candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is advancing SNA-001, a topical silver particle suspension in pivotal clinical trials aimed at treating acne and reducing light-pigmented hair. The company previously operated as Sienna Labs, Inc. and underwent significant financial restructuring, including a Chapter 11 bankruptcy filing in 2019, which transitioned to Chapter 7. Sienna Biopharmaceuticals aims to enhance patient outcomes and the practice of medicine through its targeted topical therapies.

Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Medibio Limited is a health technology company focused on the research, development, and commercialization of mental health solutions aimed at the screening, diagnosis, monitoring, and management of depression and related disorders. Operating in Australia and the United States, the company provides mental well-being solutions for businesses and develops products for healthcare providers. Medibio has created an objective test based on circadian heart rate variability, which utilizes proprietary algorithms to deliver quantifiable measures for clinical diagnosis. This test is undergoing validation in clinical studies conducted by reputable institutions, including Johns Hopkins University School of Medicine and The University of Ottawa, to support its application for FDA approval. Additionally, Medibio's technology is applicable in workplace stress and well-being markets, as well as in wearable technology and app development. Originally founded as BioProspect Limited in 1987, Medibio rebranded in 2014 and operates offices in Melbourne and the United States.

Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Dr. Lal PathLabs, founded in 1949 by Dr. S.K. Lal, a pioneer in pathology, has established itself as a leading clinical pathology laboratory in India. Originally the first of its kind in Delhi and Northern India, the organization has expanded its services to include comprehensive diagnostic offerings in pathology and radiology. Dr. Lal PathLabs operates multiple laboratories that conduct a wide range of tests across various disciplines such as biochemistry, hematology, histopathology, microbiology, immunology, and virology. These diagnostic services play a crucial role in disease prevention, monitoring, and treatment, ultimately contributing to improved health outcomes. While the company primarily generates its revenue in India, it also operates in several other countries, reflecting its growing international presence in the healthcare sector.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in developing innovative immuno-oncology therapies. The company's lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor and is currently undergoing Phase Ib/2 clinical trials targeting adenosine, an important immune checkpoint. Additionally, Corvus is advancing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib trials to inhibit adenosine production and stimulate immune responses, and is also being evaluated for its potential use in COVID-19. Other candidates in development include an antagonist of the A2B receptor and CPI-818, a small molecule inhibitor targeting interleukin-2-inducible T-cell kinase, which is also in Phase I/Ib trials. The company has established a strategic collaboration with Angel Pharmaceuticals to further develop its pipeline of targeted investigational medicines.

Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing and significantly improving survival rates for cancer patients. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in disease-specific treatments designed to target tumors effectively at their roots. As of June 1, 2016, Stemcentrx operates as a subsidiary of AbbVie, further enhancing its capabilities in cancer research and treatment development.

Intellia Therapeutics is a genome editing company based in Cambridge, Massachusetts, focused on developing curative gene-editing treatments using the CRISPR/Cas9 technology. The company aims to address severe and life-threatening genetic diseases through both in vivo and ex vivo therapeutic approaches. Its pipeline includes programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia is developing engineered cell therapies for oncological and autoimmune diseases. The company has established collaborations with various entities, including leading pharmaceutical firms and research institutions, to enhance its research and development efforts. Founded in 2014, Intellia Therapeutics holds a comprehensive intellectual property platform for the therapeutic application of CRISPR technology, positioning it at the forefront of gene editing innovation.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, focused on developing innovative therapies for patients with neurological disorders, particularly rare diseases. Founded in 2014, the company is advancing a promising pipeline of drug candidates aimed at treating conditions such as angelman syndrome and fragile X syndrome. Its lead candidate, OV101, is in Phase III clinical trials for angelman syndrome and has completed Phase II trials for fragile X syndrome. Additionally, Ovid is developing OV935, currently in Phase II trials for cyclin-dependent kinase-like 5 deficiency disorder and Dravet syndrome. The company is also researching OV329 for infantile spasms and OV881 as a microRNA gene therapy for angelman syndrome. Ovid Therapeutics has established collaborations and licensing agreements with various pharmaceutical and research organizations to enhance its development efforts. The company's commitment to addressing unmet medical needs is underpinned by strong intellectual property and a focus on safe, effective treatments for patients facing challenging neurological conditions.

Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Voyager Therapeutics is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe neurological diseases. The company's lead candidate, VY-AADC, is currently undergoing an open-label Phase 1b clinical trial for Parkinson's disease. In addition to this, Voyager's preclinical pipeline includes therapies targeting amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and various tauopathies and synucleinopathies, which encompass conditions like Alzheimer's disease and Lewy Body Dementia. Voyager Therapeutics emphasizes advancing adeno-associated virus (AAV) gene therapy through innovations in vector optimization, dosing techniques, and production processes. The company has established strategic collaborations with the University of Massachusetts and ClearPoint Neuro, along with partnerships with Brammer Bio and Fujifilm Diosynth Biotechnologies to enhance its gene therapy programs. Furthermore, Voyager has a collaboration agreement with Neurocrine Biosciences for the research, development, and commercialization of AAV-based gene therapies. Founded in 2013, Voyager Therapeutics is committed to addressing critical unmet medical needs in the field of central nervous system disorders.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies for immunotherapy and oncology. The company's lead product candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I dose escalation in multiple hematologic malignancies, as well as HGEN005, an anti-EMR1 monoclonal antibody in pre-clinical stages for eosinophilic diseases. The company collaborates with Kite Pharma to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and has partnered with the Department of Defense to further develop Lenzilumab for potential emergency use in COVID-19. Founded in 2000, Humanigen was formerly known as KaloBios Pharmaceuticals and rebranded in August 2017.